Sellas Life Sciences
SLS
11.31
-0.03
-0.26%
Sellas Life Sciences
US · SLS
#2687 by market cap
Listed 1970
11.31
-0.03
-0.26%
Live - 5344 symbols - heartbeat 254s ago
· 2026-10-08 08:30
Pre-market
11.26
-0.46%
After-hours
11.35
+0.35%
Overnight
11.32
+0.09%
- Market cap
- 2.28B
- P/E (TTM)i
- -51.41
- P/Bi
- 16.58
- EPSi
- -0.25
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SLS?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 1.90M | 7.60M | 1.00M | -- | -- | -- |
| Gross profit | -- | -- | 1.90M | 7.40M | 900.00K | -- | -- | -- |
| Selling & admin expenses | 12.77M | 9.92M | 9.60M | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Research & development | 8.77M | 7.29M | 9.28M | 15.67M | 20.27M | 24.01M | 19.10M | 16.02M |
| Operating profit | -21.54M | -17.21M | -16.98M | -19.59M | -31.95M | -37.87M | -31.51M | -28.27M |
| Pretax profit | -29.05M | -19.37M | -16.77M | -20.94M | -41.30M | -37.34M | -30.88M | -26.86M |
| Tax | -1.38M | -81.00K | -17.00K | -237.00K | -- | -- | -- | -- |
| Net profit | -27.67M | -19.29M | -16.76M | -20.70M | -41.30M | -37.34M | -30.88M | -26.86M |
| Basic EPS | -158 | -11 | -2 | -1 | -2 | -1 | -1 | 0 |
| Diluted EPS | -157.72 | -10.92 | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.86M | 3.00M | 2.87M | 3.53M | 4.12M | 4.36M |
| Research & development | 3.21M | 3.87M | 4.22M | 4.73M | 5.13M | 6.27M |
| Operating profit | -6.06M | -6.87M | -7.08M | -8.26M | -9.25M | -10.63M |
| Pretax profit | -5.81M | -6.60M | -6.79M | -7.66M | -8.41M | -9.61M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -5.81M | -6.60M | -6.79M | -7.66M | -8.41M | -9.61M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.07 | -0.07 | -0.06 | -0.05 | -0.05 | -0.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 5.84M | 8.24M | 36.93M | 23.04M | 17.76M | 3.17M | 16.33M | 75.21M |
| Cash & ST investments | 5.34M | 7.28M | 35.30M | 21.36M | 17.13M | 2.53M | 13.89M | 71.79M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 16.92M | 16.61M | 46.05M | 26.28M | 20.94M | 6.22M | 19.43M | 78.35M |
| Total current liabilities | 5.97M | 5.29M | 12.34M | 4.98M | 15.52M | 13.74M | 9.51M | 7.02M |
| Short-term debt | -- | 217.00K | 166.00K | 198.00K | 372.00K | 446.00K | 544.00K | 544.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 11,670,000.00 | 10,516,000.00 | 18,088,000.00 | 5,928,000.00 | 16,092,000.00 | 14,195,000.00 | 9,967,000.00 | 7,474,000.00 |
| Total equity | 5.25M | 6.09M | 27.96M | 20.35M | 4.85M | -7.98M | 9.47M | 70.87M |
| Retained earnings | -81.86M | -101.15M | -117.90M | -138.60M | -179.90M | -217.24M | -248.13M | -274.99M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 31.97M | 29.45M | 49.05M | 75.21M | 111.17M | 142.51M |
| Cash & ST investments | 28.40M | 25.30M | 44.32M | 71.79M | 107.10M | 138.34M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 34.96M | 32.31M | 51.56M | 78.35M | 114.18M | 145.38M |
| Total current liabilities | 6.89M | 6.00M | 5.93M | 7.02M | 6.46M | 7.57M |
| Short-term debt | 561.00K | 580.00K | 599.00K | 544.00K | 562.00K | 580.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,197,000.00 | 6,156,000.00 | 5,925,000.00 | 7,474,000.00 | 6,765,000.00 | 7,726,000.00 |
| Total equity | 27.76M | 26.15M | 45.63M | 70.87M | 107.41M | 137.66M |
| Retained earnings | -253.94M | -260.54M | -267.33M | -274.99M | -283.40M | -293.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -30.42M | -17.64M | -10.42M | -26.02M | -23.81M | -31.41M | -35.40M | -28.39M |
| Depreciation & amortization | -- | 0 | -- | -- | -- | -- | -- | -- |
| Free cash flow | -30.42M | -17.64M | -10.42M | -26.02M | -28.31M | -36.91M | -35.40M | -28.39M |
| Dividends paid | -487.00K | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 21.56M | 15.97M | 29.60M | 9.01M | 23.99M | 22.23M | 46.16M | 23.05M |
| Ending cash balance | 5.45M | 7.38M | 35.40M | 21.46M | 17.23M | 2.63M | 13.99M | 71.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -9.07M | -7.33M | -7.07M | -4.92M | -8.85M | -7.59M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -9.07M | -7.33M | -7.07M | -4.92M | -8.85M | -7.59M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 23.03M | 21.00K | 0 | 0 | 0 | 0 |
| Ending cash balance | 28.50M | 25.40M | 44.42M | 71.89M | 107.20M | 138.44M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1,127.85 | -493.05 | -98.87 | -85.70 | -327.81 | -- | -4,147.88 | -66.88 |
| ROA %i | -163.56 | -166.75 | -53.74 | -57.24 | -174.94 | -274.94 | -240.78 | -54.95 |
| ROIC %i | -1,127.85 | -474.87 | -93.45 | -82.64 | -308.84 | -- | -1,855.89 | -68.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -426.66 | -- | -- | -- |
| EBIT margin %i | -- | -- | -893.79 | -332.82 | -4,195.00 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.98 | 1.56 | 2.99 | 4.63 | 1.14 | 0.23 | 1.72 | 10.72 |
| Quick ratioi | 0.89 | 1.43 | 2.95 | 4.29 | 1.10 | 0.18 | 1.46 | 10.23 |
| Debt / assetsi | 0.00 | 1.31 | 2.15 | 3.08 | 4.51 | 14.57 | 5.15 | 1.28 |
| LT debt / equityi | -- | -- | 2.95 | 3.00 | 11.81 | -- | 4.83 | 0.64 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -144.90 | -180.71 | -84.33 | -66.88 | -43.58 | -39.63 |
| ROA %i | -91.36 | -110.74 | -66.47 | -54.95 | -39.50 | -36.54 |
| ROIC %i | -142.82 | -178.30 | -85.93 | -68.68 | -45.96 | -42.62 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.64 | 4.91 | 8.28 | 10.72 | 17.22 | 18.83 |
| Quick ratioi | 4.12 | 4.22 | 7.48 | 10.23 | 16.59 | 18.28 |
| Debt / assetsi | 2.49 | 2.28 | 1.16 | 1.28 | 0.76 | 0.51 |
| LT debt / equityi | 1.11 | 0.60 | -- | 0.64 | 0.29 | 0.11 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development of novel therapeutics for a broad range of cancer indications100.00%
Region
United States100.00%
Quote time 2026-10-08 08:30:20 · For reference only, not investment advice and not tailored to your situation.